E
Empros Pharma
Biotech & Life Sciences · Solna kommun, Sweden · Founded 2013
Pharmaceutical treatments targeting overweight and obesity with advanced release formulations for improved safety and efficacy MoreLess
Empros Pharma is a pharmaceutical company focused on developing treatments for overweight and obesity. The company's flagship product, EMP16, is currently undergoing efficacy proof of concept clinical trials, having already demonstrated a best-in-class safety profile and improved blood glucose control in early phase trials. Empros Pharma serves a market that includes overweight and pre-diabetic individuals who have limited safe and effective treatment options. The business model revolves around the development and commercialization of advanced modified release formulations that offer immediate, gastroresistant, and delayed release fractions for improved tolerability and targeted drug release. Empros Pharma generates revenue through the sale and licensing of its pharmaceutical products. The company operates in the healthcare and pharmaceutical sectors, leveraging a cross-disciplinary team of experts in nutrition, metabolism, obesity, and clinical trials to drive innovation and development.
Keywords: overweight, obesity, pharmaceutical, EMP16, clinical trials, safety profile, blood glucose control, modified release, healthcare, metabolism.
Company overview
Empros Pharma company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2013
- Headquarters
- Solna kommun, Sweden
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 26.7
Valuation & funding
Empros Pharma funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | May 2023 | $9.7M | $39M | Flerie Invest | ↗ |
| SERIES AEquity / VC | Jul 2019 | $4.8M | $19M | Flerie Invest | — |
| SEEDEquity / VC | Nov 2013 | $0 | — | Undisclosed | — |
| SPINOUT✓Other financing | Oct 2013 | $0 | — | Uppsala University | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | Profit | Margin |
|---|---|---|---|---|
| 2026 | $965K | 0% | −$1.4M | -145.9% |
| 2025 | $965K | 0% | −$1.4M | -145.9% |
| 2024 | $965K | -82.9% | −$1.4M | -145.9% |
| 2023 | $5.6M | +174.3% | ||
| 2022 | $2.1M | +129.3% | ||
| 2021 | $895K | -56.4% | ||
| 2020 | $2.1M | — |
Growth signals
Empros Pharma website traffic
Latest recorded traffic for Empros Pharma is 1.7K monthly website visits, up 91% over the last three months. Empros Pharma's team grew 0% over the past year.
Comparisons
Empros Pharma compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Empros Pharma's talent
Source: Dealroom Talent Intelligence.
Investors
3 investors on Empros Pharma's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Empros Pharma has talent and traffic
team presence
In the news
Latest news about Empros Pharma
Recent press, funding announcements, and product moves mentioning Empros Pharma — open to read from the original sources.
Market sentiment
What the market is saying about Empros Pharma
An AI-synthesized read of the highest-engagement posts about Empros Pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Empros Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.